![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
3MB |
| Item Type: | Article |
|---|---|
| Title: | IL-36 signaling as a drug target in Crohn's disease patients with IL36RN mutations |
| Creators Name: | Hecker, J., Plattner, C., Cancino, C.A., Löscher, B.S., Saurenbach, J., Letizia, M., Rieder, D., Freise, I., Koop, K., Neufert, C., Kunkel, D., Al Khatim, Z., Schaafs, L.A., Schütz, A., Becker, C., Atreya, R., Trajanoski, Z., Franke, A., Sonnenberg, E., Hegazy, A.N., Siegmund, B. and Weidinger, C. |
| Abstract: | The IL-36 signaling pathway has recently been identified as a key regulator of intestinal homeostasis and inflammation. However, the role of mutations in the IL-36R signaling pathway in the pathogenesis of inflammatory bowel disease remains unclear. We here identified four Crohn’s disease patients with heterozygous missense mutations in the IL-36 receptor antagonist (IL36RN, IL-36RA). Experimental overexpression and functional assays demonstrated that two identified mutations resulted in reduced expression of IL-36RA. In-depth immune profiling of one IL36RN-mutated patient revealed an increased response of PBMCs to IL-36 stimulation and elevated serum levels of IL-36-regulated cytokines. Administration of the IL-36R-blocking antibody spesolimab to this patient resulted in a reduction of intestinal inflammation and alterations in immune cell composition and function. Our findings indicate that pathogenic IL36RN mutations may contribute to the pathogenesis of Crohn’s disease in a subset of patients and that inhibiting IL-36 signaling could offer a personalized therapeutic approach for these patients. |
| Keywords: | IL-36 Signaling, Crohn’s Disease, Personalized Therapy, Genetics |
| Source: | EMBO Molecular Medicine |
| ISSN: | 1757-4676 |
| Publisher: | EMBO Press / Wiley |
| Date: | 30 May 2025 |
| Additional Information: | Leif S.-H. Ludwig and Ashley Sanders are members of the TRR241 IBDome Consortium. |
| Official Publication: | https://doi.org/10.1038/s44321-025-00245-z |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
